Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

ary efficacy endpoint in the induction phase of the study is the attainment of a clinical response defined as a decrease from baseline in the Crohn's Disease Activity Index (CDAI) score of at least 70 points. In a separate clinical trial, Traficet-EN is also being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role.

"We are very pleased to have completed enrollment of more than 430 patients for the PROTECT-1 study at clinical sites in 17 countries worldwide. This represents an important milestone in the development of this promising new drug, as well as an impressive accomplishment by a committed group of investigators throughout the world and our entire clinical team," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx. "Following completion of PROTECT-1, our goal is to expeditiously advance additional clinical development of Traficet-EN to support regulatory filings worldwide."

ChemoCentryx's Second-Generation CCR9 Program

ChemoCentryx is also advancing a second-generation, orally-active CCR9 antagonist through preclinical development and anticipates a regulatory filing to enable first-in-human studies on this compound in the second half of the year. Structurally diverse from Traficet-EN, this second-generation CCR9 antagonist strengthens ChemoCentryx's proprietary position in the CCR9 arena, and gives the company the potential to pursue additional gastrointestinal and other clinical indications with discrete compounds.

The CCR9 program is a part of a strategic alliance that ChemoCentryx signed in 2006 with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD) for the discovery and development of small molecule antagonists targeting four defined chemokine and chemoattractant receptors. Under the terms of the agreement, ChemoCentryx is responsible for advancing produc
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
... Reportlinker.com announces that a new market research ... Merck & Co., Inc.: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast performance ... sector. The profile encompasses global company strategy, portfolio ...
Cached Medicine Technology:Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... , ... The condition where veins are enlarged and gnarled is known as ... discomfort. Those who spend a lot of time on their feet and standing are ... what it can to create awareness and provide a cure in observance of Senior ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... study suggests that extra iron for infants who don,t need ... over optimal iron supplement levels and could have huge implications ... for 25 years of research show problems with lack of ... deal, it,s really unexpected," said Dr. Betsy Lozoff, University of ...
... Actress Joins Thousands of Participants in Inspirational Closing ... Local Breast Cancer Organizations, WASHINGTON, May 4 ... Foundation Reese Witherspoon was a special guest at ... D.C. this weekend,cheering on and joining walkers on ...
... 2008 Annual Meeting in San,Diego, CA, NEW YORK, ... MD, is the new President of the American Society ... 2,400,members, is the leading national organization of board-certified plastic,surgeons ... The,election of new officers was held on May 4, ...
... parents have a surprisingly low-level knowledge of typical ... physical, social and emotional growth, according research from ... suggest that such false parenting assumptions can not ... of much-needed cognitive stimulation, will be presented Sunday, ...
... always connected, researchers say , , FRIDAY, May 2 (HealthDay ... experienced by Alzheimer,s disease patients and the sleep woes ... from the University of Washington, in Seattle, found that ... always connected. , The researchers studied 44 older adults, ...
... Ripping out and tearing down to create a divinely ... and the economic downturn may be leading more families ... has found that parents need to be aware that all ... due to exposure to lead. , The study ...
Cached Medicine News:Health News:Iron supplements might harm infants who have enough 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Long Island Plastic Surgeon is New President of American Society for Aesthetic Plastic Surgery 2Health News:Long Island Plastic Surgeon is New President of American Society for Aesthetic Plastic Surgery 3Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Sleep Troubles Vary Between Alzheimer's Patients, Caregivers 2Health News:Fixing up 'this old house' may increase young 2Health News:Fixing up 'this old house' may increase young 3
Industry leader in the design and manufacturing of GP Lenses. Abba holds the CLMA seal of excellence award....
The inventory system designed for Wholesale Distributors and centralized distribution centers for Optical chains....
... Express is a powerful, fully automated information ... productivity, reduce errors, increase profitability, and all ... Express program has been designed and developed ... point of purchase software. This fully integrated ...
Easy to use practice management software....
Medicine Products: